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ABSTRACT:
Objectives: The homozygous GH receptor (GHR) pseudoexon (6Ψ) mutation leads 
to growth hormone insensitivity (GHI) with clinical and biochemical 
heterogeneity. We investigated whether transcript heterogeneity (6Ψ-GHR to 
WT-GHR transcript ratio) and/or concurrent defects in other short stature (SS) 
genes contribute to this.
Methods:  6Ψ-GHR and WT-GHR mRNA transcripts of 4 6Ψ patient (height SDS -
4.2 to -3.1) and 1 control fibroblasts were investigated by RT-PCR. Transcripts 
were quantified by qRT-PCR and delta delta CT analysis and compared using 
ANOVA with Bonferroni correction. In eleven 6Ψ patients, 40 genes known to 
cause GHI/SS were analysed by targeted next generation sequencing.
Results: RT-PCR confirmed 6Ψ-GHR transcript in the 6Ψ patients but not control. 
6Ψ-GHR transcript levels were comparable in patients 1 and 3 but significantly 
different among all other patients. The mean 6Ψ:WT transcript ratios ranged from 
29-71:1 for patients 1-4 and correlated negatively with height SDS (R=-0.85; 
p<0.001). Eight deleterious variants in 6 genes were detected but the number of 
gene hits did not correlate with the degree of SS in individual 6Ψ patients.
Conclusion: Variable amounts of 6Ψ- and WT-GHR transcripts were identified in 
6Ψ patients but no 6Ψ transcript was present in the control. Higher 6Ψ:WT GHR 
transcript ratio correlated with SS severity and may explain the phenotypic 
variability. Analysis of known SS genes suggested that phenotypic variation is 
independent of the genetic background. This is the first report of transcript 
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heterogeneity producing a spectrum of clinical phenotypes in different individuals 
harbouring an identical homozygous genetic mutation.
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INTRODUCTION:
Growth Hormone Insensitivity (GHI) is characterised by growth failure, IGF1 
deficiency and normal or elevated GH levels. GHI encompasses a spectrum of 
genetic, phenotypic, and biochemical abnormalities associated with growth 
failure1,2. Monogenic defects of the GH-IGF1 axis leading to GHI have been 
identified in the GHR3, STAT5B4, IGFALS5, PAPPA26 and IGF17 genes.
Splicing is the process by which introns are precisely identified and excised with 
the remaining exons united to form a translatable message8. Intronic DNA 
frequently encodes potential exonic sequences9. These “pseudoexons” are 
sequences between 50-300 nucleotides in length with apparently viable 5′ and 3′ 
splice sites10,11. Under normal circumstances, they are actively suppressed and 
not recognised by the splicing machinery10,12-15. However, point mutations in 
intronic DNA sequences can lead to the creation of new donor (5’), acceptor (3’) 
splice or branch sites and activation of “pseudoexons”. This often occurs within 
100 nucleotide bases of the canonical splice site resulting in the inclusion of 
intronic sequences immediately flanking the exonic sequence16. Inclusion of 
intronic sequences by aberrant splicing is a recognised rare cause of several 
genetic diseases including neurofibromatosis type 1, cystic fibrosis, Duchenne and 
Becker muscular dystrophies8,17. 
The intronic growth hormone receptor (GHR) pseudoexon (6Ψ) mutation was first 
reported in 2001 in two sets of siblings from a highly consanguineous Pakistani 
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family with growth failure and features of relatively mild GHI18. In 2007, an 
additional seven 6Ψ patients were reported with a wider range of short stature 
(SS) phenotypes19. In 2013, Walenkamp et al described 2 further 6Ψ patients 
with growth failure followed by partial catch-up growth without treatment20. We 
recently reported the spectrum of clinical and biochemical features in 20 6Ψ 
subjects, which included eleven previously reported individuals and nine 
additional patients21. 
The GHR 6Ψ mutation (c.618+792A>G) is a homozygous point mutation in the 
final nucleotide of the pseudoexon, altering the 5’ pseudoexon splice site in 
intron 6 of the GHR gene. This results in activation of the pseudoexon sequence, 
efficient splicing and inclusion of an additional 108 bases between exons 6 and 7. 
This results in the inclusion of 36 amino acids in the extracellular domain of the 
GHR protein18 and functional work demonstrated that the mutant GHR protein 
impaired trafficking rather than signalling22. 
Under normal circumstances, the GHR pseudoexon is disregarded i.e. not spliced 
into the mature GHR mRNA. Previous work confirmed that binding of 
heterogenous nuclear ribonucleoprotein E1 (hnRNP E1) and U1 small nuclear 
ribonucleoprotein (snRNP) to the pre-spliceosomal complex prevented 6Ψ 
inclusion8. 
GHR 6Ψ mutation patients exhibit a wide spectrum of clinical and biochemical 
variability, even between individuals within the same kindred21. The height SDS of 
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20 GHR 6Ψ patients previously described21 varied between -1.7 and -5.9 with IGF1 
SDS between -1.0 and -6.8. Additionally, 50% patients had ‘classical’ GHI facial 
features and the remainder had completely normal facial appearance21. 
Splice mutations may not always be 100% efficient in causing aberrant splicing 
and normal (wild type) and mutant transcripts may exist concurrently due to 
competitive use of normal and mutant splice sites. Previous data suggested that, 
alongside the abnormally spliced GHR transcript, a small amount of normally 
spliced wild-type GHR mRNA was present in GHR 6Ψ patients18. 
Analysis of cDNA of patients carrying different splice mutations of the same gene 
have shown that multiple abnormal splicing events occur alongside the 
production of the normal splice product, leading to a spectrum of phenotypes23-
25. However, transcript variability has not previously been investigated in 
individuals with identical splice mutations.
The range of phenotypes observed in patients with the GHR 6Ψ mutation may be 
related to the presence of transcript heterogeneity i.e. the ratio of abnormal 
(mutant) to normal (wild type) GHR transcript. Genetic and environmental factors 
may also play a role in defining this ratio19. We investigated for the first time, 
whether GHR gene transcript heterogeneity and/or concurrent defects in other 
known short stature genes contributed to the observed clinical variability of 6Ψ 
subjects. 
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Subjects and Methods: 
Subjects
The subjects were diagnosed with homozygous intronic GHR 6Ψ mutations at our 
centre between 2001 and 201418,19,21. The referring physicians completed a 
proforma detailing the clinical and biochemical details at the time of DNA 
sampling for genetic analysis21 and was prior to starting any growth promoting 
therapy. Height measurements were obtained using a wall-mounted stadiometer. 
Height was expressed as SDS according to the appropriate UK-WHO growth 
national standards26,27. IGF1 values were expressed as SDS based on the age and 
sex appropriate ranges provided by the host institution.
Fibroblast culture
Dermal fibroblasts from 4 GHR 6Ψ subjects (Patients 1-4) from 2 consanguineous 
Pakistani families were obtained by punch skin biopsies, which were performed 
according to established protocols28,29 after written informed consent was 
obtained. Control human fibroblasts (normal neonatal male dermal fibroblast cell 
line) were obtained from American Type Culture Collection (ATCC, USA). 
Fibroblast cells were cultured in 75 cm2 cell culture flasks (Greiner Bio-One, 
Germany) in High Glucose-DMEM (Sigma-Aldrich, UK) supplemented with 20% 
foetal bovine serum (Invitrogen), 50 units/ml penicillin and 50 μg/ml 
streptomycin.
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Reverse- transcriptase PCR (RT-PCR) 
RNA was extracted from fibroblast cell lines using the RNAEasy kit (Qiagen, UK) as 
per the manufacturer's instructions. One microgram RNA was reverse transcribed 
using the Moloney Murine Leukemia Virus Reverse Transcriptase (M-MLV RT) mix 
(Thermofisher Scientific, UK) according to manufacturer’s protocol. cDNA 
products from 4 patients and 1 control subject were amplified using the following 
intron skipping primers (Figure 1a):
1. Primers directed to exon 5 of the GHR gene (forward; 
AGTGCAACCAGATCCACC) and the junction of exons 6 and 7 (reverse; 
GGAAAATGATGGACCCTATA) to amplify the wild-type (WT-GHR) transcript 
(Reaction 1)
2. Primers directed to the GHR 6Ψ (forward; GGCACAGATCACTCCCAG) and 
the junction of exons 7 and 8 (reverse; GATTTCTACTTTCCATGGCTC) to 
amplify the mutant (6Ψ-GHR) transcript (Reaction 2)
Thermocycling conditions were: heated lid 110°C; 30 cycles at 95°C for 30s, 65°C 
to 55°C for 30s and 72°C for 30s followed by 10 cycles at 95°C for 30s, 60°C for 30s 
and 72°C for 30s. Products were visualised on a 2% agarose gel and verified by 
Sanger sequencing (GATC Biotech; https://www.gatc- biotech.com).
Quantitative RT-PCR (qRT-PCR)
The relative levels of WT-GHR and 6Ψ-GHR mRNA transcripts were quantified by 
quantitative RT-PCR using the primer sets above (Reactions 1 & 2). Expression 
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levels of the two transcripts were determined quantitatively by the MX3000 real-
time PCR system (Stratagene) using SYBR green (Kapabiosystems, USA).  10 ng 
cDNA was added per 10 μL reaction. Thermocycling conditions were: 1 cycle at 
95°C for 3 mins, 40 cycles at 95°C for 3s, 60°C for 20s and 72°C for 10s and 1 cycle 
at 95°C for 1 min, 60°C for 30s and 72°C for 30s. 
The relative expression levels of the two transcripts were compared in the 4 
patients and 1 control. Gapdh was used as the internal reference gene and 5 
technical repeats for each patient were performed. For each experiment, five 
independent RNA extractions were assayed with three technical replicates. 
Relative mRNA expression (stated as mean±SD) was calculated by delta delta CT 
analysis (ΔΔCT) and values in patients and control were compared using one-way 
ANOVA with Bonferroni correction. P<0.05 was taken as statistical significance.
Genetic analysis by targeted gene sequencing
Genomic DNA was isolated from peripheral blood leukocytes (Qiagen DNeasy Kit) 
from 11 6Ψ subjects, including patients 1, 2 & 4 from whom skin fibroblasts were 
obtained. No DNA was available for patient 3. Targeted sequencing of the coding, 
promotor and intronic regions (2000 bp upstream and 500 bp downstream of 
each target gene) of 40 short stature genes was undertaken (Table 1). This was 
processed on an Illumina HiSeq 2500 sequencing platform with paired end of 100 
and a designated average coverage of 100x (Otogenetics, Norcross, GA). The raw 
data from Otogenetics were analysed using DNA Nexus (DNAnexus Inc., Mountain 
View, CA, USA) by aligning to the H. sapiens GRCh37–b37 (1000 genomes Phase 1) 
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reference genome with BWA-MEM FastQ Readmapper. VCF files were generated 
by Vendor Human Exome GATK-Lite Variant Caller (Unified Genotyper). 
The resulting VCF files were uploaded to Ingenuity Variant Analysis (Qiagen, 
Germany) and results were analysed with the following filters: call quality ≥20, 
read depth ≥10, data outside 5% of most exonically variable 100 base windows in 
healthy public genomes. Common variants were filtered out by excluding those 
with a minor allele frequency of ≥0.5% in the 1000 genomes, ExAC and the NHLBI 
exomes. 
Genetic variants were investigated in silico by SIFT (score 0, predicted deleterious 
to 1, predicted benign), PolyPhen-2 (score 0, predicted benign to 1, predicted 
deleterious) and CADD (Combined Annotation Dependent Depletion) score to 
predict the functional outcome. The CADD score assesses the negative effect of 
single nucleotide variants as well as insertion/deletions variants. A scaled CADD 
score of 20 represents a variant that is amongst the top 1% deleterious variants 
and a scaled CADD score of 30 means that the variant is in the top 0.1%.
Ethical approval 
The study was approved by the Health Research Authority, East of England - 
Cambridge East Research Ethics Committee (REC reference: 17/EE/0178). 
Informed written consent for genetic research, skin biopsy and publication of 
clinical details was obtained from parents / carers and the patients where 
appropriate. 
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Results
Clinical phenotypes 
The subjects studied had a range of clinical and biochemical heterogeneity as 
previously described. Patients 1 (height SDS -3.6 and IGF1 SDS -2.0) and 4 (height 
SDS -3.1 and IGF1 SDS -2.5) were first cousins from a consanguineous Pakistani 
family with no dysmorphic facial features. Patients 2 (height SDS -4.2 and IGF1 
SDS -2.5) and 3 (height SDS -3.8 and IGF1 SDS -2.3) are siblings from another 
consanguineous Pakistani family. Both had typical facial features of GHI with mid-
facial hypoplasia, depressed nasal bridge and prominent forehead. The mean age 
at presentation of the 4 patients was 3.2 years (range 2.6-3.8 years) (Table 2).
The mean age at presentation of the 11 6Ψ patients who underwent targeted 
gene sequencing was 4.8 years (range 1.2 to 9.9 years), mean height SDS -4.1 
(range -3.0 to -5.1 SDS) and mean IGF1 SDS was -2.6 (range -4.0 to -2.0). 10/11 
and 1/11 were from consanguineous Pakistani families and a non-consanguineous 
Indian family, respectively. Consistent with our previous report21, 6/12 (50%) had 
facial features of GHI, as above.
Wild-type and mutant GHR transcript expression
In order to amplify the WT-GHR transcript, a RT-PCR reaction was performed 
(Reaction 1), using primers directed to exon 5 and the junction of exons 6 and 7 of 
the GHR gene (Figure 1a). The WT-GHR transcript (193 base pairs, bp) was 
identified in all 4 6Ψ subjects and the control. The 6Ψ-GHR transcript was 
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amplified by a RT-PCR reaction (Reaction 2) using primers directed to the GHR 6Ψ 
and the junction of exons 7 and 8 of the GHR gene (Figure 1a). The mutant 6Ψ-
GHR transcript (228 bp) was identified in all 6Ψ subjects but not the control 
(Figure 1b). Sanger sequencing verified all the predicted cDNA sequences. 
Quantification of the wild-type and mutant GHR transcripts
qRT-PCR quantified the relative levels of the WT-GHR and mutant 6Ψ-GHR 
transcripts, using the primer sets above (Reactions 1 & 2). 
WT-GHR mRNA expression (mean±SD) relative to control was 0.055±0.021, 
0.022±0.014, 0.055±0.018 and 0.049±0.034 for patients 1-4, respectively (Figure 
2a). This was significantly lower in all patients compared to control (1.001 ± 
0.016); all p values <0.001. This suggests that only small amounts of WT-GHR 
transcript are present in the GHR 6Ψ patients.
Mutant 6Ψ-GHR mRNA expression was calculated relative to patient 1, rather 
than control, as mutant transcript expression was negligible in the control 
compared to the 6Ψ subjects. Mutant 6Ψ-GHR mRNA expression (mean±SD) 
relative to patient 1 (1.003±0.004) were 0.552±0.061, 1.003±0.180 and 
0.40±0.069 for patients 2-4, respectively and 0.001±0.0003 for control. There was 
no significant difference in 6Ψ-GHR transcript levels between patients 1 & 3. 
However, 6Ψ-GHR transcript levels were significantly different between all the 
other patients (1 & 2, 1 & 4, 2 & 3 and 3 & 4; p<0.001 and patients 2 & 4; 
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p=0.017) (Figure 2b). This confirms variable amounts of mutant 6Ψ-GHR 
transcript in the GHR 6Ψ subjects, with negligible levels in control. 
The mean 6Ψ:WT transcript ratios for patients 1-4 were 39:1, 71:1, 47:1 and 29:1, 
respectively (Table 2). These values correlated negatively with height SDS (R=-
0.85, p value <0.001) (Figure 2c). This would suggest that shorter patients have 
transcript ratios in favour of the mutant GHR.
Genetic analysis
We analysed 11 6Ψ subjects (which included patients 1, 2 & 4) for genetic 
variants in 40 known human short stature genes. This revealed 8 predicted 
deleterious variants in 6 genes (IGFALS, OBSL1, CBL, IGF1R, ACAN and CUL7) in 8 
of the 11 6Ψ subjects (Table 3). Patients 9 and 10 had compound heterozygous 
missense variants in CUL7 and IGFALS, respectively (Table 3). The remaining 6/8 
variants were monoallelic (patients 2, 4, and 5-8). 4/6 were missense and 2/6 
were in-frame insertions. 6/8 variants had a CADD score of >20. Patients 4 and 6 
had in-frame insertions in CBL and IGF1R genes (CADD score 12.6 and not known, 
respectively). None of the patients had homozygous variants identified. 
We classified the pathogenicity of the variants according to the American College 
of Medical Genetics and Genomics and the Association for Molecular Pathology 
(ACMG/AMP)’s standards and guidelines for the interpretation of sequence 
variants30 (Table 3). 7/8 of the predicted deleterious variants were variants of 
‘Uncertain Significance’30. Although the missense variants are very rare in 
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populations (allele frequency <0.001 in the gnomAD database31) and in silico 
variant prediction tools support a deleterious effect on the gene, they fall into the 
category of ‘uncertain significance’ as they do not meet the criteria for being 
either pathogenic or benign30. Furthermore, although the IGF1R  heterozygous 
c.109_123dupATCGACATCCGCAAC, p.I37_N41dup in-frame insertion variant 
fulfils 2 moderate criteria for pathogenicity30 i.e. protein length changes as a 
result of in-frame deletion in a non-repeat region and is absent from controls as 
well as large databases (allele frequency 0.002 in the gnomAD database31),  it 
does not strictly meet the ACMG/AMP criteria for pathogenicity and hence is 
classified as ‘uncertain significance’30. The CBL heterozygous c.125_127dupACC, 
p.H42dup variant is ‘likely benign’30 as it is an in-frame insertion in a repetitive 
region without known function and there is 1 homozygote in the gnomAD 
database31.
Patients 2 and 8 with heterozygous ACAN variants did not have advanced bone 
maturation, early onset osteo-arthritis or intervertebral disc disease. Patient 6 
(heterozygous in-frame IGF1R insertion) had normal birth weight, normal IGF-1 
SDS, no developmental delay and consequently also did not fulfil the published 
criteria for the identification of patients with suspected IGF1R mutations (total 
score <3)32. Patients 4 and 7 with CBL variants had no cardiac defects or 
developmental delay. Therefore, although these defects could potentially 
contribute to the short stature, no phenotypic features associated with these 
heterozygous genetic defects were detected.
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In the four patients who underwent transcript heterogeneity analysis, 3 
underwent genetic sequencing of short stature genes. Patient 2 had a 
heterozygous missense ACAN variant. Patient 4 had a heterozygous missense 
OBSL1 variant and a heterozygous in-frame CBL variant. Patient 1 had no 
predicted deleterious variants. 
Reviewing all patients assessed on the gene panel (Table 3; n=11), there was no 
correlation between the number of predicted deleterious genetic variants (0, 1 or 
2) and the degree of short stature (height SDS) in the individual 6Ψ patients, i.e. 
patient 4 had 2 variants and was not significantly shorter than those with 1 (n=7) 
or no variant(s) (n=3) (Table 3). Additionally, the mean (±SD) height SDS of 
patients with heterozygous or compound heterozygous variants in autosomal 
dominant inherited genes (ACAN, CBL, IGF1R) (-3.78±0.67) was not significantly 
different from that of patients with heterozygous or compound heterozygous 
variants in autosomal recessive inherited genes (OBSL, CUL7, IGFALS) or patients 
with no deleterious variants (-4.1±0.56), p=0.39.
Discussion
GH insensitivity (GHI) is a rare disorder caused by mutations in multiple GH-IGF1 
axis genes. Homozygous GHR mutations are the commonest cause of ‘classical’ 
GHI and are associated with a wide range of clinical and biochemical 
phenotypes33. More recently, it has been noted that several other short stature 
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disorders such as 3M, Noonan Syndrome (NS) and Silver-Russell Syndrome (SRS) 
overlap with GHI2,34-37.
Milder or ‘non-classical’ GHI cases are being increasingly recognised owing to 
advent of next generation sequencing techniques and an increased awareness of 
this group of disorders. Other molecular defects of the GH-IGF1 axis that cause 
‘non-classical’ or milder GHI phenotypes include dominant negative GHR38-41 and 
STAT5B42 gene mutations, heterozygous IGF143-45, IGF246,47 and IGFALS48,49 
mutations, homozygous PAPPA26 mutations and the GHR pseudoexon (6Ψ) 
mutation18-21. Non-classical GHI is an important clinical entity and the 
prevalence may be higher than classical GHI2. Approximately 70 different GHR 
gene mutations have been reported in more than 300 patients1,2. A recent UK 
study37 reporting the genetic diagnoses obtained from candidate gene and whole 
exome sequencing (WES) in a selected group of 107 patients with GHI showed 
that the GHR 6Ψ mutation contributed 25% (8/32) GHR mutations and 16% (8/51) 
of all genetic diagnoses. 
The GHR 6Ψ mutation is notable as striking phenotypic variability is observed 
between different patients harbouring the same homozygous point mutation, 
even amongst members of the same kindred21. We hypothesise that several 
factors alone or in combination could contribute to the phenotypic variability 
observed between individual patients and include: 1. Differences in the levels of 
mutant vs wild type GHR transcripts 2. Concurrent genetic variants contributing to 
the degree of growth failure 3. Environmental factors and 4. Genetic variability in 
Page 17 of 46 Accepted Manuscript published as EC-20-0026. Accepted for publication: 12-Feb-2020
Copyright © 2019 the authors Downloaded from Bioscientifica.com at 02/18/2020 07:07:21AM
via free access
the cellular processes that regulate the mutant and WT GHR proteins. These are 
discussed in detail below.
David et al19 suggested that the spectrum of clinical phenotypes observed in the 
GHR 6Ψ patients may be due to competitive use of both wildtype and 6Ψ mutant 
splice sites resulting in different ratios of the two transcripts. The current study 
tested the hypothesis that transcript heterogeneity could account for the 
phenotypic differences, particularly the severity of growth failure in the 6Ψ 
subjects.
We found variable levels of mutant 6Ψ-GHR mRNA expression among all patients 
except patients 1 and 3, who had similar height deficits of -3.6 and -3.8, 
respectively. Our work implies that the splicing of the GHR pseudoexon is highly 
inconsistent as variable quantities of mutant transcripts are produced in different 
individuals with the same mutation. Furthermore, consistent with our previous 
work18, we confirmed the existence of WT-GHR transcript in the 6Ψ subjects 
alongside the mutated 6Ψ-GHR transcript. This demonstrates that normal as well 
as abnormal splicing events co-exist in these subjects. Our results also confirm 
that a higher WT to mutant transcript ratio correlates negatively with the height 
SDS of the patients i.e. greater mutant pseudoexon inclusion may lead to a more 
severe phenotype. 
Interestingly, consistent with previous published work18, no GHR 6Ψ transcript 
was detected in the control subject. This would indicate that under normal 
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circumstances, the GHR pseudoexon splice site is not recognised by the splicing 
machinery thereby preventing its inclusion in the mature mRNA. This 
corroborates the work by Akker et al8 who showed that the heterogenous 
nuclear ribonucleoprotein E1 (hnRNP E1) and small nuclear ribonucleoprotein U1 
(snRNP U1) bind to the relatively weak “wild-type” 5’ GHR pseudoexon splice site 
in the pre-spliceosomal complex and silence it. The A>G base change at the 5’ 
splice site in 6Ψ patients does not create a new splice site but increases the base 
pair match of the pre-mRNA with the snRNP U1. Therefore, the spliceosome 
recognises the GHR pseudoexon sequence and it is included in the mature mRNA 
of patients carrying the mutation19.
Genotype-phenotype correlations secondary to variable splicing have been 
reported in 3 previous studies. Zhu23 and Lemahieu et al24 investigated the 
association of different splice mutations of the WASP (Wiskott-Aldrich syndrome 
protein) gene with the clinical phenotypes of patients with WAS and X-linked 
thrombocytopaenia. Another study by Gurvich et al25 investigated the correlation 
between the clinical phenotypes of 2 patients and the splicing efficiency of 2 
different intronic pseudoexon mutations in the DMD (Duchenne muscular 
dystrophy) gene. All 3 studies demonstrated that relative amounts of mutant to 
normal transcripts positively correlated with the severity of the phenotypes of 
affected individuals. However, these studies examined different splice site 
mutations of the individual genes. Our work is the first to report the phenotypic 
impact of transcript heterogeneity in patients with an identical homozygous splice 
mutation. 
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The potential underlying mechanism(s) leading to a spectrum of phenotypes in 
subjects with the same genetic mutation are unclear. Gurvich et al25 proposed 
that the difference in splicing efficiency between the 2 different DMD gene 
mutations could be attributed to the strength of the donor splice sites created by 
the mutation and/or the strength of the cryptic acceptor splice sites in the wild-
type sequence which are further activated by the point mutations. This 
explanation would not be applicable to our patients as the 6Ψ intronic point 
mutation leads to activation of the same 5’ donor splice site in all the subjects. 
David et al19 also suggested that the genetic background of individual patients 
and/or environmental factors may play a role in determining the differential use 
of WT vs mutant splice sites and thus generation of variable quantities of normal 
vs mutated transcript. Variations in the core spliceosome machinery (comprising 
hnRNP and snRNP) and variations in genes encoding RNA processing/RNA-binding 
factors can influence alternative splicing50-52. It is possible that differences in 
these factors between 6Ψ patients regulate the differential use of the mutated 
and WT splice sites and thus determine the amount of mutant vs WT transcript 
generated.
It is feasible that the GHI phenotype, particularly the severity of the growth failure 
observed in the 6Ψ patients, is influenced by genetic variants in different genetic 
loci. We sought concurrent defects in genes known to cause short stature, GH 
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insensitivity and overlapping phenotypes e.g. Noonan, Silver-Russell and 3M 
Syndrome in 11 6Ψ patients. 
Analysis of 40 genes (including intronic and promoter regions) revealed a 
significant proportion (73%) of 6Ψ subjects had predicted deleterious 
heterozygous or compound heterozygous genetic variants. Of these, 3 variants in 
ACAN, IGF1R and CBL genes are recognised to have an autosomal dominant 
pattern of inheritance leading to short stature53-55. It is possible that these 
variants contributed to the growth failure in patients 2, 4, 6, 7 & 8. However, 
none of these patients had additional phenotypic features that would be 
consistent with the identified additional genetic variant. Furthermore, there was 
no difference in height SDS between the patients with heterozygous/compound 
heterozygous variants in genes with an autosomal dominant pattern of 
inheritance compared to patients with heterozygous/compound heterozygous 
variants in genes with an autosomal recessive inheritance or patients with no 
deleterious variants. This implies that the ACAN, IGF1R and CBL gene variants 
identified did not impact significantly on the patient’s phenotypes. Unfortunately, 
we were unable to perform segregation studies as parental DNA was not available 
for any of the subjects. However, consistent with our findings, a previous study of 
2 6Ψ patients also demonstrated that other genetic variants did not contribute to 
the severity of the phenotypes20.
Interestingly, given that the majority of patients have consanguineous family 
structures, no homozygous variants were detected. We were also unable to 
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identify a correlation between the number of predicted deleterious variants and 
the severity of short stature in the individual GHR 6Ψ patients studied. This 
indicates that concurrent defects in this subset of known short stature, GHI and 
overlapping disorders genes do not appear to contribute to the growth 
phenotype in these patients. We cannot, however, rule out an impact of other 
known short stature genes or currently undiscovered short stature genes. It is 
also possible that multiple genes with smaller effect size could account for some 
or all of the clinical variation.
Genotyping a region spanning 17.10 Mb around the GHR gene on chromosome 5 
and analysis of the complex single polymorphic region in intron 9 of the GHR in 5 
GHR 6Ψ families showed the same genotype for all affected members, suggesting 
the presence of a common ancestor19. Furthermore, 19/22 the known GHR 
pseudoexon patients are of Pakistani ethnicity18-21. This implies that the GHR 6Ψ 
patient cohort share a common genetic background. This is comparable to the 
p.E180 splice GHR mutation, found predominantly in individuals from Ecuador, 
Brazil and Chile where a shared genetic background flanking the splice mutation 
was identified56,57. First degree relatives who are heterozygous carriers of the 
p.E180 mutation are modestly shorter than non-carrier relatives58. This is in 
contrast to our cohort, where heterozygous carrier parents of 6Ψ patients had 
normal stature19. 
It is recognised that a multitude of environmental factors such as nutrition, socio-
economic status and adverse environmental conditions affect childhood 
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growth59,60. It is possible that any of these factors contribute to the phenotypic 
variability observed in our patient cohort. However, as there are marked 
differences between affected individuals within the same kindred, environmental 
factors are unlikely to be very significant.
It is feasible that differences in processing, trafficking and degradation of the 
mutant and WT GH receptor proteins account for the clinical differences19. 
Maamra et al22 confirmed that the mutant GHR 6Ψ protein compromised normal 
cell surface trafficking but signalling was unimpaired.  Therefore, variability in 
genes regulating these cellular processes might conceivably have a greater 
influence on the mutant 6Ψ GHR protein than the WT GHR. Further work 
exploring this hypothesis is required.
It is important to acknowledge that our study has several limitations. Firstly, GHR 
transcript ratios were studied in only 4 6Ψ patients. Furthermore, 1 of the 4 
patients was not assessed on the gene panel. Our work would not identify 
variants in other known short stature genes not included in the panel or defects 
in currently undiscovered short stature genes. Additionally, the phenotypic 
spectrum of individual genetic defects is expected to broaden as more patients 
are reported. Finally, we did not explore the mechanisms underlying the observed 
variable splicing or genetic variability which might affect GHR protein processing, 
trafficking and degradation. Further work is required to address these. 
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In conclusion, our work shows that there is a variable ratio of mutated and WT 
GHR mRNA transcripts in GHR 6Ψ patients. The mutated GHR 6Ψ transcript is not 
normally spliced in unaffected subjects. Patients with more severe phenotypes 
i.e. lower height SDS, have a GHR transcript ratio in favour of the mutant GHR. 
The reason for the variable splicing in different patients with the same mutation is 
fascinating. The genetic background of individuals may influence this. However, 
our preliminary work does not suggest that variants in candidate SS genes 
contribute significantly to the variability of growth failure. This is the first 
indication that variable splicing and transcript heterogeneity can lead to a range 
of short stature phenotypes in subjects harbouring the same genetic mutation.
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Figure titles and legends:
Figure 1. Reverse Transcriptase PCR (RT-PCR) of wild-type (WT) and mutant 
transcripts in the 6Ψ and control subjects 
a) Schematic diagram of the GHR gene showing the position of the 6Ψ 
pseudoexon and intron skipping primers. 6Ψ, mutant pseudoexon transcript; WT, 
wild type GHR transcript b) 2% agarose gel showing products of RT-PCR Reaction 
2: 6Ψ transcript (228 bp) in all 4 6Ψ patients (patients 1-4) but not in the control 
subject. Bp, base pairs.
Figure 2. Quantitative RT-PCR (qRT-PCR)
a) Box and Whisker Plot with jitter showing qRT-PCR of WT GHR mRNA fold 
change relative to Control. Box plots show the mean, upper and lower quartiles 
and range; IQR= interquartile range; p values calculated by one way ANOVA with 
Bonferroni correction. Pt, patient. *** P value <0.001.  b) Box and Whisker Plot 
with jitter showing qRT-PCR of 6Ψ-GHR mRNA fold change relative to Pt 1. Box 
plots show the mean, upper and lower quartiles and range; IQR= interquartile 
range; p values calculated by one-way ANOVA with Bonferroni correction. Pt, 
patient; ***p value <0.001; **p value=0.017. c) Scatter plot showing the 
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correlation between the height SDS at presentation and the mean 6Ψ:WT 
transcript ratios in the four 6Ψ patients. Pt, patient; 6Ψ, pseudoexon; WT, wild 
type; R, Pearson correlation coefficient. 
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 Figure 1. Reverse Transcriptase PCR (RT-PCR) of wild-type (WT) and mutant transcripts in the 6Ψ and 
control subjects 
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 Figure 2a). Quantitative RT-PCR (qRT-PCR). Box and Whisker Plot with jitter showing qRT-PCR of WT GHR 
mRNA fold change relative to Control 
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 Figure 2b). Quantitative RT-PCR (qRT-PCR). Box and Whisker Plot with jitter showing qRT-PCR of 6Ψ-GHR 
mRNA fold change relative to Pt 1 
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 Figure 2c). Scatter plot showing the correlation between the height SDS at presentation and the mean 
6Ψ:WT transcript ratios in the four 6Ψ patients. 
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Table 1. Short stature genes included in the genetic analysis of 11 6Ψ subjects
GHR IGFBP1 SOS2 MAP2K1 (MEK1)
IGFALS IGFBP2 RAF1 MAP2K2 (MEK2)
STAT5B IGFBP4 BRAF A2ML1
IGF1 IGFBP5 NRAS LZTR1
PAPPA-2 IGF2 KRAS SHOC2
IGF1R OBSL1 HRAS ARAF
IGFBP3 CCDC8 RRAS NF1
PAPPA CUL7 CBL NPR2
STAT3 PTPN11 RIT1 ACAN
JAK2 SOS1 RASA2 SHOX
Genetic analysis included review of known (GHR, IGFALS, STAT5B, IGF1, PAPPA2 and IGF1R) and 
putative (IGFBP3, PAPPA, STAT3, JAK2, IGFBP1, IGFBP2, IGFB4, IGFBP5) monogenic defects of the GH-
IGF1 axis leading to GHI and IGF1 resistance phenotypes. We also sought variants in genes associated 
with overlapping short stature syndromes2,34-37 3M (OBSL1, CCDC8, CUL7), Silver-Russell (IGF2,) and 
Noonan (PTPN11, SOS1, SOS2, RAF1, BRAF, NRAS, KRAS, HRAS, RRAS, CBL, RIT1, RASA2, MAP2K1, 
MAP2K2, A2ML1, LZTR1, SHOC2, ARAF, NF2) syndromes. Other genes associated with short stature ( 
ACAN61,62, NPR2 63, SHOX64) were also included in the analysis.
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Table 2. Phenotypic features and 6Ψ-GHR to wild type-GHR transcript ratios in the 
four 6Ψ subjects
Patient Sex Age      
(yrs)
Height 
SDS
IGF1 SDS Facial
features
Mean
6Ψ/WT 
transcript
ratio
1 M 3.8 -3.6 -2.0 N 39.2:1
2 F 3.7 -4.2 -2.5 Y 70.7:1
3 M 2.6 -3.8 -2.3 Y 46.9:1
4 M 2.8 -3.1 -2.5 N 29.4:1
 M, Male; F, Female; Facial features of classical GHI (frontal bossing, mid-facial hypoplasia); N, No; 
Y, Yes; 6Ψ, mutant pseudoexon transcript; WT, wild type GHR transcript.
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Table 3. Genetic variants identified in known short stature genes in the 6Ψ subjects 
Pt
Age
(yrs)
Height 
SDS
IGF-1 
SDS
Gene transcript Translation SIFT Score Polyphen
CADD 
Score
ACMG/AMP
classification
1 3.8 -3.6 -2.0 No deleterious variants detected N/A N/A N/A N/A N/A
2 3.7 -4.2 
-2.5 ACAN 
Het c.1223A>G, p.Q532H
Missense Damaging
Prob
Damaging
23.7
Uncertain 
significance
3 2.6 -3.8 -2.3 No DNA available N/A N/A N/A N/A N/A
OBSL1
Het c.2671A>G, p.T891A
Missense Damaging
Prob
Damaging
26.8
Uncertain 
significance
4
2.8 -3.1
-2.5
CBL 
Het c.125_127dupACC, p.H42dup
In-frame NK NK 12.6
Likely Benign
5 5.7 -4.5 
-2.5
OBSL1
Het c.2671A>G, p.T891A
Missense Damaging
Prob
Damaging
26.8
Uncertain 
significance
6 1.2 -4.4 IGF1R In-frame NK NK NK Uncertain 
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-2.2 Het 
c.109_123dupATCGACATCCGCAAC, 
p.I37_N41dup
significance
7 7.0 -4.2 -2.5
CBL 
Het c.2216C>T, p.S739F 
Missense Damaging Benign 23.1
Uncertain 
significance
8 5.7 -3.0 
-2.9
ACAN
Het c.1596G>C, p.R132C
Missense Damaging
Prob
Damaging
27.9
Uncertain 
significance
9 4.3 -4.1 -4.0
CUL7 
Het c.464G>A, p.G155E
c.620G>A, p.G207E 
Missense Damaging
Prob
Damaging
26.9
Uncertain 
significance
10 2.5 -4.4 NK
IGFALS
Het c.544C>A, p.L220M
c.658C>A, p.L182M
Missense Damaging
Prob
Damaging
23.5
Uncertain 
significance
11 5.7 -4.7 -3.1 No deleterious variants detected N/A N/A N/A N/A N/A
12 9.9 -5.1 -2.1 No deleterious variants detected N/A N/A N/A N/A N/A
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Pt, Patient; Ht, Height; NK, not known; Prob, probably; CADD, Combined Annotation Dependent Depletion; N/A, Not applicable; c. coding DNA sequence where nucleotide 
1 is the A of the ATG-translation initiation codon (NCBI Reference Sequences: for ACAN, NM_013227.2; for OBSL1, NM_015311.2; for CBL, NM_005188.3; for IGF1R, 
NM_000875.3; for CUL7, NM_001168370.1 and for IGFALS, NM_004970.2); ACMG/AMP classification, classification as per the American College of Medical Genetics and 
Genomics and the Association for Molecular Pathology’s standards and guidelines for the interpretation of sequence variants30. Patients 1-4 are the 6Ψ patients analysed 
for WT-GHR and 6Ψ-GHR transcript ratios (Table 2).
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